PPARA and obesity disorder: For example, administration of both, PPARα agonists such as fibrates and FGF21 lowered LDL-cholesterol, raised HDL-cholesterol, improved insulin sensitivity and prevented diet-induced obesity in rhesus monkeys and rodents [4,27-30].